ข้ามไปยังเนื้อหาหลัก

ENGLISH · EVIDENCE OVERVIEW

Cardarine / GW501516
evidence profile

Experimental PPAR-beta/delta agonist; not a SARM. This page provides a concise English boundary and links back to the complete source-rich Thai profile.

Cardarine / GW501516: conceptual scientific illustration for Clinical / Endocrine Pharmacology
VISUAL GUIDE · Cardarine / GW501516

Clinical / Endocrine Pharmacology

Conceptual educational illustration. It is not a treatment outcome and does not establish efficacy or safety.

QUICK ANSWER · AEO / GEO

Cardarine, GW501516 and GW1516 identify an experimental PPAR-beta/delta agonist, not a SARM or anabolic steroid. Short controlled human studies reported lipid-biomarker changes but did not establish cardiovascular-event reduction, fat loss, endurance benefit or long-term safety. Animal studies report tumour-promoting signals in susceptible models; these do not quantify human incidence but preclude a proven-safety claim. WADA 2026 prohibits GW501516 at all times as a metabolic modulator.

01

ENTITY FACTS

What should readers identify first?

MOLECULECardarine / GW501516
PHARMACOLOGYExperimental PPAR-beta/delta agonist; not a SARM
PRIMECORE CLASSB
EVIDENCE GRADEB
RESEARCH TOPICClinical / Endocrine Pharmacology
LAST REVIEWED2026-09-01
02

EVIDENCE BOUNDARY

What this overview does not establish

  • An evidence grade does not rank this molecule against another treatment.
  • A molecule name does not establish the identity, purity or regulatory status of a product.
  • Animal, cell or biomarker findings do not automatically establish human clinical benefit.
  • Approval in one country or indication does not transfer globally.
03

FAQ · ANSWER ENGINE

Frequently asked questions

What is Cardarine / GW501516?

Cardarine / GW501516 is described pharmacologically as Experimental PPAR-beta/delta agonist; not a SARM. Cardarine, GW501516 and GW1516 identify an experimental PPAR-beta/delta agonist, not a SARM or anabolic steroid. Short controlled human studies reported lipid-biomarker changes but did not establish cardiovascular-event reduction, fat loss, endurance benefit or long-term safety. Animal studies report tumour-promoting signals in susceptible models; these do not quantify human incidence but preclude a proven-safety claim. WADA 2026 prohibits GW501516 at all times as a metabolic modulator.

Does Cardarine / GW501516 have strong evidence?

PrimeCoreBio records Evidence Grade B. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.

Is Cardarine / GW501516 approved everywhere?

No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.

Medical Disclaimer

Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.

LINE · สอบถามข้อมูลทั่วไปติดต่อฝ่ายข้อมูลทั่วไปLINE · GENERAL SUPPORTGeneral enquiries@primecoreสำหรับข้อมูลทั่วไปเท่านั้น · ไม่มีบริการด้านการขายหรือคำแนะนำทางการแพทย์General information only · No sales or medical advice